HRT vs Veozah (Fezolinetant): Which Menopause Treatment Is Right for You?

What Is HRT and What Does It Treat?

Hormone replacement therapy replenishes estradiol and, when needed, progesterone to relieve the symptoms caused by ovarian hormone decline. For most perimenopausal and postmenopausal women under age 60 or within 10 years of their final menstrual period, the benefits of HRT outweigh its risks according to the 2022 Menopause Society (NAMS) position statement. Beyond hot flashes and night sweats, HRT addresses genitourinary syndrome of menopause (GSM), sleep disruption, mood changes, and bone loss.

The Women's Health Initiative (WHI) enrolled 27,347 women and initially raised concerns about breast cancer and cardiovascular risk, but subsequent reanalysis showed that women aged 50 to 59 who used conjugated equine estrogen (CEE) alone had a reduced all-cause mortality compared with placebo (hazard ratio 0.73 to 95% CI 0.55 to 0.98) [1]. The breast cancer signal was specific to the combination arm (CEE plus medroxyprogesterone acetate) and was not observed with estrogen-only therapy in women who had a hysterectomy [2]. That distinction now shapes prescribing: women with an intact uterus need a progestogen to protect the endometrium, while those post-hysterectomy may take estrogen alone.

Current FDA-approved estrogen formulations include oral estradiol tablets (0.5 mg, 1 mg, 2 mg), transdermal patches (releasing 0.025 to 0.1 mg/day), transdermal gels (EstroGel, Divigel), and estradiol spray (Evamist) [3]. Each formulation is plant-derived and structurally identical to endogenous 17-beta estradiol, meeting the clinical definition of bioidentical.

What Is Veozah (Fezolinetant) and How Does It Work?

Fezolinetant is a selective neurokinin 3 (NK3) receptor antagonist. It blocks the action of neurokinin B on hypothalamic KNDy neurons, which are overactive during menopause and trigger the thermoregulatory dysfunction underlying hot flashes and night sweats. The mechanism is entirely non-hormonal.

The FDA granted approval on May 12, 2023, based on the SKYLIGHT 1 and SKYLIGHT 2 phase 3 trials [4]. In SKYLIGHT 1 (N=501), fezolinetant 45 mg reduced moderate-to-severe vasomotor symptom (VMS) frequency by 59.2% from baseline at week 12, versus 39.4% for placebo (P<0.001) [5]. SKYLIGHT 2 (N=498) replicated those findings, showing a 63.3% frequency reduction at week 12 with 45 mg versus 43.6% for placebo (P<0.001) [6]. The SKYLIGHT 4 open-label safety study followed patients for 52 weeks and found no new safety signals beyond those identified in the key trials [7].

Veozah does not affect estrogen levels, does not require progestogen co-administration, and carries no VTE or breast cancer risk from its mechanism. That profile makes it genuinely distinct from HRT rather than simply a weaker substitute.

Comparing Efficacy: Hot Flashes, Night Sweats, and GSM

HRT is broader in scope. Transdermal estradiol 0.05 mg/day reduces VMS frequency by 70 to 75% in randomized trials and also resolves vaginal dryness, dyspareunia, and recurrent UTIs associated with GSM [8]. Fezolinetant addresses only VMS. Women with significant GSM symptoms who choose Veozah will still need local (vaginal) estrogen or ospemifene for urogenital relief, because fezolinetant has no effect on vaginal epithelium.

Bone protection is another gap. The NAMS guideline notes that estrogen is an FDA-approved therapy for osteoporosis prevention in postmenopausal women [9]. Fezolinetant has no data supporting fracture risk reduction.

Sleep quality improves with both treatments through distinct pathways. Estrogen reduces night-sweat-driven awakenings and may have direct effects on sleep architecture [10]. Fezolinetant improves sleep disturbance scores indirectly by cutting nocturnal VMS frequency, with SKYLIGHT 1 and 2 both showing statistically significant improvements on the MENQoL sleep subscale [5][6].

For women whose primary complaint is hot flashes and who have no GSM or bone-density concerns, the two treatments produce broadly comparable VMS relief. The difference is roughly 15 percentage points in favor of HRT for raw frequency reduction, but individual response varies considerably.

Oral vs Transdermal Estradiol: Why Delivery Route Matters

This is one of the most clinically significant and underappreciated choices within HRT. Oral estradiol undergoes first-pass hepatic metabolism, raising sex hormone-binding globulin (SHBG), C-reactive protein, and triglycerides, and producing supraphysiologic estrone levels [11]. Transdermal estradiol bypasses the liver, delivers estradiol directly into the bloodstream, and does not meaningfully alter coagulation factors or SHBG.

The ESTHER study (N=881, case-control) found that oral estrogen was associated with a fourfold increased risk of VTE (odds ratio 4.2 to 95% CI 1.5 to 11.6), while transdermal estradiol showed no significant VTE elevation (OR 0.9 to 95% CI 0.5 to 1.6) [12]. Women with a history of VTE, obesity, or thrombophilia should strongly prefer the transdermal route based on this evidence.

Transdermal options each have practical tradeoffs:

• Patch (e.g., Climara, Vivelle-Dot): Changed once or twice weekly. Adhesion problems can occur in heat or humidity. Provides steady-state estradiol delivery. Generic patches start around $30/month.
• Gel (e.g., Divigel, EstroGel): Applied daily to the thigh or arm. Alcohol-based; dries in 2 to 5 minutes. Dose-adjustable by packet size (Divigel 0.1%, 0.25 mg to 1 mg). Must avoid skin-to-skin transfer to partners or children for at least 1 hour after application [13].
• Spray (Evamist): One to three sprays per day on the inner forearm. Each spray delivers 1.53 mg estradiol; approximately 1.35% is absorbed. Convenient for women who dislike the feel of gel.

Oral estradiol remains appropriate for women without VTE risk factors who prefer a simple daily pill and have no hepatic concerns. Doses of 0.5 to 2 mg daily cover most symptom severities.

Patch vs Gel: Which Transdermal Estradiol Form Is Better?

Neither patch nor gel is categorically superior. The choice depends on adherence, skin sensitivity, and daily routine. A patch must adhere for 3.5 to 7 days and can peel with sweat or swimming; some women develop contact dermatitis at the adhesive site. A gel requires a brief daily application and precise hand-washing afterward to prevent inadvertent transfer.

Pharmacokinetically, patches produce slightly more stable 24-hour estradiol levels compared with gels, which show modest peaks 2 to 4 hours after application [14]. For most symptom management purposes, this difference is not clinically meaningful. Women who exercise heavily, live in humid climates, or have sensitive skin may find gel more reliable. Women who value minimal daily effort may prefer a twice-weekly patch.

Bioidentical vs Synthetic Hormones: Clearing Up the Confusion

"Bioidentical" means the hormone molecule is structurally identical to the one the human body produces. All FDA-approved estradiol products (patches, gels, sprays, and most oral tablets) are bioidentical 17-beta estradiol derived from plant sources (wild yam or soy) [3]. Synthetic estrogens like conjugated equine estrogens (Premarin) contain a mixture of estrogen compounds, some of which are not identical to human estradiol.

The term "bioidentical" is frequently co-opted by compounding pharmacies to market custom-mixed preparations containing estriol, estradiol, and estrone (so-called "biest" or "triest"), often in pellet or cream form. The FDA has not approved these preparations, and the American College of Obstetricians and Gynecologists (ACOG) states in Committee Opinion 532 that "there is no scientific evidence supporting improved efficacy or safety for individualized compounded bioidentical hormones over conventional hormone therapy" [15].

Compounded preparations also lack standardized potency testing. A 2019 analytical study found that 14 of 36 compounded progesterone creams contained <90% of labeled potency, and 3 contained >110%, raising both under-treatment and overdose concerns [16]. For endometrial protection, only adequately dosed oral or vaginal FDA-approved micronized progesterone (Prometrium, 200 mg for 12 days/cycle or 100 mg nightly continuous) has demonstrated histologic protection in peer-reviewed trials [17].

Compounded vs FDA-Approved HRT

FDA-approved products pass manufacturing quality standards, have published pharmacokinetic data, and carry labeling that reflects actual clinical trial outcomes. Compounded products may be appropriate in narrow circumstances: a woman with a documented allergy to an inactive ingredient in every approved product, or a need for a dose or combination not commercially available.

Outside those specific situations, compounded HRT introduces unnecessary uncertainty. Pellet implants in particular deliver variable estradiol levels that cannot be easily titrated or discontinued; supraphysiologic estradiol concentrations above 200 pg/mL have been documented in pellet users [18]. The Endocrine Society's 2015 clinical practice guideline on compounding states that "compounded preparations should not be used when FDA-approved preparations are available" [19].

The HealthRX clinical team uses the following decision framework when a patient asks about compounded HRT versus FDA-approved options:

1. Identify whether any FDA-approved product meets the clinical need (dose, route, formulation).
2. If yes, prescribe the approved product.
3. If no approved option fits (documented excipient allergy, unique dose requirement confirmed by serology), compound from a 503B outsourcing facility with USP <795> compliance, and monitor serum hormone levels at 6 and 12 weeks.
4. Document the clinical rationale in the chart for medico-legal clarity.

This approach aligns with ACOG Committee Opinion 532 [15] and FDA guidance on compounding [20].

Who Should Choose HRT?

HRT is the first-line choice per the 2022 Menopause Society position statement for women under 60 or within 10 years of menopause onset who have bothersome VMS, GSM, or who are at elevated fracture risk and seek prevention [9]. Specific populations who benefit most include:

• Women with premature ovarian insufficiency (POI, defined as ovarian failure before age 40), where HRT reduces long-term cardiovascular and bone risks [21].
• Women with severe GSM alongside VMS, since only estrogen treats both simultaneously.
• Women with osteopenia or osteoporosis who want one agent addressing both skeletal and symptomatic needs.
• Women post-hysterectomy, who can take estrogen alone and avoid progestogen-related side effects entirely.

Absolute contraindications to systemic HRT include active or recent (within 12 months) hormone receptor-positive breast cancer, active VTE or arterial thromboembolic event, unexplained vaginal bleeding, and severe active liver disease [9][22].

Who Should Choose Veozah (Fezolinetant)?

Fezolinetant fits a specific clinical profile. Women who cannot use HRT due to contraindications, women who have completed breast cancer treatment and seek non-hormonal VMS relief, and women who simply prefer to avoid hormones are reasonable candidates. The NAMS 2023 nonhormonal management position statement lists NK3 receptor antagonists as an evidence-based option for moderate-to-severe VMS [23].

Prescribing cautions are real. Fezolinetant is metabolized primarily by CYP1A2; co-administration with strong CYP1A2 inhibitors like fluvoxamine is contraindicated because it can increase fezolinetant exposure by more than fivefold [4]. Liver enzyme monitoring is recommended: obtain ALT/AST at baseline, 3 months, and 6 months. In SKYLIGHT 4, hepatocellular injury (defined as ALT >3x upper limit of normal) occurred in 2 of 599 fezolinetant-treated patients [7]. That rate is low but not zero.

Cost is a practical barrier. The list price of Veozah is approximately $550 per month. Most commercial insurance plans require prior authorization, and coverage criteria differ. Transdermal estradiol patch generics cost $30 to $75 per month at most retail pharmacies.

Side Effect Profiles Side by Side

HRT common side effects: Breast tenderness (most frequent in the first 1 to 3 months), breakthrough bleeding or spotting when initiating cyclic or continuous combined regimens, bloating with oral formulations, and skin irritation at patch sites. These typically resolve within 8 to 12 weeks of dose adjustment [22].

Fezolinetant common side effects: Abdominal pain (reported in 4.4% vs 2.2% placebo in SKYLIGHT 1), diarrhea, insomnia, and hot flush paradoxically in a minority during initiation [5]. The hepatic signal, though uncommon, necessitates monitoring absent with HRT.

Neither treatment is associated with cognitive decline at therapeutic doses. Observational data from the Cache County Study (N=1,889) suggested that HRT initiated near menopause onset may reduce Alzheimer's risk, but this has not been confirmed in randomized trial data and should not be cited as an indication [24].

The Progestogen Question: Endometrial Safety

Any woman with a uterus who takes systemic estrogen must also take a progestogen to prevent endometrial hyperplasia and cancer. The PEPI trial (N=875) confirmed that unopposed estrogen produced endometrial hyperplasia in 62% of participants over 3 years, versus 1% with combined estrogen-progestogen therapy [17].

FDA-approved micronized progesterone (Prometrium 100 mg nightly continuous or 200 mg for 12 days per cycle) is the preferred progestogen for most patients because of its neutral lipid profile and lower association with breast cancer compared with synthetic progestins in the E3N cohort study (N=80,377) [25]. Synthetic progestins like medroxyprogesterone acetate (MPA) remain effective for endometrial protection but carried the breast cancer signal seen in the WHI combination arm [2].

Veozah requires no progestogen. That simplicity benefits women who experience progestogen intolerance (mood changes, bloating, sleep disruption on MPA or norethindrone).

Monitoring and Follow-Up

For HRT, NAMS recommends reassessment at 3 to 6 months after initiation to evaluate symptom control, side effects, and regimen adherence, then annually thereafter [9]. Mammography should follow age-appropriate screening guidelines; HRT does not change the recommended interval. Bone density (DEXA) is appropriate at age 65 or earlier if fracture risk factors are present, per USPSTF 2018 guidance [26].

For fezolinetant, liver function testing at baseline, 3 months, and 6 months is the primary monitoring requirement per the FDA prescribing information [4]. Discontinue if ALT exceeds 3x the upper limit of normal.

Serum estradiol levels during HRT are not routinely indicated for symptom management but may be useful when a patient reports poor symptom control despite adequate adherence, or when supraphysiologic levels are suspected (as in pellet therapy). A target range of 40 to 100 pg/mL is a common clinical reference point for symptomatic postmenopausal women on standard-dose transdermal therapy [18].